JP7741981B2 - Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用 - Google Patents

Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用

Info

Publication number
JP7741981B2
JP7741981B2 JP2024522590A JP2024522590A JP7741981B2 JP 7741981 B2 JP7741981 B2 JP 7741981B2 JP 2024522590 A JP2024522590 A JP 2024522590A JP 2024522590 A JP2024522590 A JP 2024522590A JP 7741981 B2 JP7741981 B2 JP 7741981B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
pharmaceutically acceptable
mmol
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024522590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524766A (ja
JP2024524766A5 (https=
Inventor
イェントン チャン
シアンルー リー
Original Assignee
シェンチェン コーイェー ライフ テクノロジーズ，カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シェンチェン コーイェー ライフ テクノロジーズ，カンパニー，リミティド filed Critical シェンチェン コーイェー ライフ テクノロジーズ，カンパニー，リミティド
Publication of JP2024524766A publication Critical patent/JP2024524766A/ja
Publication of JP2024524766A5 publication Critical patent/JP2024524766A5/ja
Application granted granted Critical
Publication of JP7741981B2 publication Critical patent/JP7741981B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024522590A 2021-06-29 2022-06-28 Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用 Active JP7741981B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110724794.6A CN115536648B (zh) 2021-06-29 2021-06-29 一类抑制rna解旋酶dhx33的多环化合物及其应用
CN202110724794.6 2021-06-29
PCT/CN2022/102010 WO2023274251A1 (zh) 2021-06-29 2022-06-28 一类抑制rna解旋酶dhx33的多环化合物及其应用

Publications (3)

Publication Number Publication Date
JP2024524766A JP2024524766A (ja) 2024-07-05
JP2024524766A5 JP2024524766A5 (https=) 2025-02-04
JP7741981B2 true JP7741981B2 (ja) 2025-09-18

Family

ID=84690417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522590A Active JP7741981B2 (ja) 2021-06-29 2022-06-28 Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用

Country Status (5)

Country Link
US (1) US20240182454A1 (https=)
EP (1) EP4378940A4 (https=)
JP (1) JP7741981B2 (https=)
CN (1) CN115536648B (https=)
WO (1) WO2023274251A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
CN115969980B (zh) * 2022-12-30 2023-10-24 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗胃癌的药物中的应用
CN116099004B (zh) * 2022-12-30 2024-01-30 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗膀胱癌的药物中的应用
CN116036282B (zh) * 2022-12-30 2023-12-26 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗前列腺癌的药物中的应用
CN115944739B (zh) * 2022-12-30 2023-12-19 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗黑色素瘤的药物中的应用
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
CN116478147B (zh) * 2023-04-25 2025-08-29 深圳开悦生命科技有限公司 抑制rna解旋酶dhx33活性的氘代化合物、合成方法、药物组合物及用途
CN118955485A (zh) * 2023-05-15 2024-11-15 深圳开悦生命科技有限公司 一种化合物的晶型、药物组合物及用途
CN118415976A (zh) * 2024-05-09 2024-08-02 深圳开悦生命科技有限公司 多环化合物注射剂及其制备方法
CN118561829A (zh) * 2024-05-23 2024-08-30 深圳开悦生命科技有限公司 一种含吡咯环的化合物的合成方法及其检测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2013036749A1 (en) 2011-09-07 2013-03-14 University Of Kansas Hcv helicase inhibitors and methods of use thereof
JP2016521762A (ja) 2013-06-18 2016-07-25 ４エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｙｒｋキナーゼ阻害剤としての２，３−ジヒドロベンゾフラン−５−イル化合物
WO2020037079A1 (en) 2018-08-14 2020-02-20 Epizyme, Inc. Substituted indoles and methods of use thereof
CN112661754A (zh) 2020-12-30 2021-04-16 成都开悦生命科技有限公司 一类抑制rna解旋酶dhx33的多环化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
CN101006052B (zh) * 2004-07-30 2013-11-06 埃克塞利希斯股份有限公司 作为药用制剂的吡咯衍生物
WO2008085302A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
IN2012DN02474A (https=) * 2009-08-28 2015-08-21 Arena Pharm Inc
MX2021006347A (es) * 2018-11-30 2021-10-13 Epizyme Inc Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2.
CN110295233B (zh) * 2019-07-08 2023-04-25 深圳开悦生命科技有限公司 DHX33基因作为Ras驱动的癌症分子靶点的应用
CN112538078B (zh) * 2020-12-23 2024-03-19 成都开悦生命科技有限公司 一类抑制dhx33解旋酶的多环化合物
EP4714456A2 (en) * 2020-12-16 2026-03-25 Shenzhen Keye Life Technologies, Co., Ltd. Polycyclic compounds for inhibiting rna helicase dhx33 and use thereof
CN112898284B (zh) * 2021-03-01 2022-06-21 深圳开悦生命科技有限公司 一类抑制rna解旋酶dhx33的化合物及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2013036749A1 (en) 2011-09-07 2013-03-14 University Of Kansas Hcv helicase inhibitors and methods of use thereof
JP2016521762A (ja) 2013-06-18 2016-07-25 ４エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｙｒｋキナーゼ阻害剤としての２，３−ジヒドロベンゾフラン−５−イル化合物
WO2020037079A1 (en) 2018-08-14 2020-02-20 Epizyme, Inc. Substituted indoles and methods of use thereof
CN112661754A (zh) 2020-12-30 2021-04-16 成都开悦生命科技有限公司 一类抑制rna解旋酶dhx33的多环化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Chemical Information and Modeling，2015年，Vol. 55，pp. 2443-2454

Also Published As

Publication number Publication date
JP2024524766A (ja) 2024-07-05
EP4378940A4 (en) 2024-09-04
WO2023274251A1 (zh) 2023-01-05
EP4378940A1 (en) 2024-06-05
CN115536648A (zh) 2022-12-30
US20240182454A1 (en) 2024-06-06
CN115536648B (zh) 2024-09-17

Similar Documents

Publication Publication Date Title
JP7741981B2 (ja) Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用
CN112538078B (zh) 一类抑制dhx33解旋酶的多环化合物
JP6768857B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
ES2316546T3 (es) 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
CN102131801B (zh) 1,2-二取代的杂环化合物
CN112661754B (zh) 一类抑制rna解旋酶dhx33的多环化合物
CN113811300A (zh) Tead转录因子的新型小分子抑制剂
JP7530510B2 (ja) Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用
CN112898284B (zh) 一类抑制rna解旋酶dhx33的化合物及其应用
CA2792339A1 (en) Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
US11617738B2 (en) 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use
CN114634491B (zh) 一类抑制rna解旋酶dhx33的多环化合物
CN115536655B (zh) 一类抑制rna解旋酶dhx33的多环化合物
JP2026513172A (ja) 置換されたスルタム化合物誘導体及びその薬学的用途
CN120379999A (zh) 新型irak4抑制剂以及抑制并降解irak4蛋白的化合物及其制备方法和应用
EP4219453A1 (en) Pyrazole compound and preparation method therefor and use thereof
CN114728965B (zh) 吡啶并杂环类化合物、其制备方法及用途
CN109305957B (zh) 苯基吡啶类化合物及其在dpp-4酶抑制剂的应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241119

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250905

R150 Certificate of patent or registration of utility model

Ref document number: 7741981

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150